Abstract:The projected trajectory of multidrug resistant tuberculosis (MDR-TB) epidemics depends on the reproductive fitness of circulating strains of MDR M. tuberculosis (Mtb) . Previous efforts to characterize the fitness of MDR Mtb have found that Mtb strains of the Beijing sublineage (Lineage 2.2.1) may be more prone to develop resistance and retain fitness in the presence of resistance-conferring mutations than other lineages. Using Mtb genome sequences from all culture-positive cases collected over two years in Moldova, we estimate the fitness of Ural (Lineage 4.2) and Beijing strains, the two lineages in which MDR is concentrated in the country. We estimate that the fitness of MDR Ural strains substantially exceeds that of other susceptible and MDR strains, and we identify several mutations specific to these MDR Ural strains. Our findings suggest that MDR Ural Mtb has been transmitting efficiently in Moldova and poses a substantial risk of spreading further in the region. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This publication was made possible by CTSA Grant Number UL1 TR001863 from the National Center for Advancing Translational Science (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethical approval was obtained for this study from the Ethics Committee of Research of the Phthisiopneumology Institute in Moldova and the Yale University Human Investigation Committee (Number 2000023071). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors

Author Correction: The recent rapid expansion of multidrug resistant Ural lineage Mycobacterium tuberculosis in Moldova

Erratum to “The Feasibility of Xpert MTB/RIF Testing to Detect Rifampicin Resistance among Childhood Tuberculosis for Prevalence Surveys in Northern China”

The recent rapid expansion of multidrug resistant Ural lineage Mycobacterium tuberculosis in Moldova

The recent rapid expansion of multidrug resistant strains of Mycobacterium tuberculosis Ural lineage 4.2 in the Republic of Moldova

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Author Correction: Tandem gene duplications contributed to high-level azole resistance in a rapidly expanding Candida tropicalis population

Author Correction: Autophagy restricts Mycobacterium tuberculosis during acute infection in mice

Author Correction: Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase

Corrigendum: Molecular Epidemiology and Characteristics of CTX-M-55 Extended-Spectrum β-Lactamase-Producing Escherichia coli From Guangzhou, China

Author Correction: BHMT Polymorphism and Susceptibility to PTE in Chinese Patients.

Author Correction: Accelerated antimicrobial discovery via deep generative models and molecular dynamics simulations

Corrigendum: Molecular epidemiology and mechanism of Klebsiella pneumoniae resistance to ertapenem but not to other carbapenems in China

Author Correction: Chemical genomics with pyrvinium identifies C1orf115 as a regulator of drug efflux

Author Correction: Understanding epistatic networks in the B1 β-lactamases through coevolutionary statistical modeling and deep mutational scanning

Corrigendum: Comparative genomics revealed fluoroquinolone resistance determinants and OmpF deletion in carbapenem-resistant Escherichia coli

Erratum for Poonawala et al., "Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis"

Correction: Corrigendum: Construction and application of a co-expression network in Mycobacterium tuberculosis

Correction: A Single-Step Sequencing Method for the Identification of Mycobacterium tuberculosis Complex Species

Corrigendum: Digitizing tuberculosis treatment monitoring in Wuhan city, China, 2020–2021: Impact on medication adherence

Corrigendum: Diagnostic efficiency of metagenomic next-generation sequencing for suspected spinal tuberculosis in China: a multicenter prospective study

Author Correction: 137 ancient human genomes from across the Eurasian steppes